M. Palanki

发表

Inhibition of Nuclear Factor-κB in T Cells Suppresses Lung Fibrosis

N. Bruno, Tatsuya Hayashi, E. Gabazza, 2007 .

Inhibition of nuclear factor-kappaB in T cells suppresses lung fibrosis.

N. Bruno, Tatsuya Hayashi, E. Gabazza, 2007, American journal of respiratory and critical care medicine.

Collagen-Induced Arthritis Inhibitor on In Vitro Cytokine Production B κ The Effect of a T Cell-Specific NF -

P. Tak, A. Manning, G. Firestein, 2000 .

Solution-phase parallel synthesis using ion-exchange resins

M. Suto, M. Palanki, L. M. Gayo-Fung, 1998 .

Development of a Novel Long-Acting Antidiabetic FGF21 Mimetic by Targeted Conjugation to a Scaffold Antibody

K. Retting, K. Ogilvie, B. Violand, 2013, The Journal of Pharmacology and Experimental Therapeutics.

The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.

V. Almendro, F. López‐Soriano, S. Busquets, 2007, International journal of oncology.

Development of a long acting human growth hormone analog suitable for once a week dosing.

Danielle E. Dettling, Mark Horn, F. Brunel, 2013, Bioorganic & medicinal chemistry letters.

Expert Opinion on Therapeutic Patents

A. Manning, M. Palanki, 1999 .

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis.

G. M. Iverson, J. Hachmann, D. S. Jones, 1995, Journal of medicinal chemistry.

The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes.

G. Noronha, Xinshan Kang, J. Hood, 2007, Bioorganic & medicinal chemistry letters.

Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.

G. Noronha, Xinshan Kang, W. Wrasidlo, 2007, Journal of medicinal chemistry.

Novel inhibitors of AP-1 and NF-kappaB mediated gene expression: structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)++ +pyrimidi ne-5-carboxylate.

A. Manning, M. Suto, A M Manning, 2000, Bioorganic & medicinal chemistry letters.

Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide].

A. Manning, B. Bennett, M. Suto, 2000, Journal of medicinal chemistry.

Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e (C2BI) alkylation subunit.

D. Boger, M. Palanki, P. Kitos, 1993, Bioorganic & medicinal chemistry.

Functional analogs of CC-1065 and the duocarmycins incorporating the 9a-(chloromethyl)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (C2BI) alkylation subunit: synthesis and preliminary DNA alkylation studies

D. Boger, M. Palanki, 1992 .

Structure–Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-κB Mediated Gene Expression

M. Goldman, M. Palanki, P. Erdman, 2002 .

The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studies

A. Manning, B. Bennett, M. Suto, 2003 .

Inhibitors of ABL and the ABL-T315I mutation.

G. Noronha, Xinshan Kang, J. Hood, 2008, Current topics in medicinal chemistry.

Functional Analogues of CC‐1065 and the Duocarmycins Incorporating the 9a‐(Chloromethyl)‐1,2,9,9a‐tetrahydrocyclopropa(c)benz(e)indol‐4‐one ( C2BI) Alkylation Subunit: Synthesis and Preliminary DNA Alkylation Studies.

D. Boger, M. Palanki, 1993 .

Solution‐Phase Parallel Synthesis Using Ion‐Exchange Resins.

M. Suto, M. Palanki, L. M. Gayo-Fung, 1998 .

Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity.

M. Palanki, Moorthy S S Palanki, 2002, Current medicinal chemistry.

In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.

A. McPherson, G. Noronha, J. Hood, 2006 .

Development of novel benzotriazines for drug discovery

G. Noronha, R. Soll, E. Dneprovskaia, 2009, Expert opinion on drug discovery.

Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.

Hong Zhu, Steven Hu, Joel Renick, 2008, Journal of medicinal chemistry.

Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.

Hong Zhu, Feng Shi, Steven Hu, 2007, Bioorganic & medicinal chemistry letters.

Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.

Joel Renick, Kathy Barrett, Richard Soll, 2006, Bioorganic & medicinal chemistry letters.

2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3′,5′-bis (trifluoromethyl)phenyl)carboxamide: A Potent Inhibitor of NF-ϰB- and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry.

D. W. Anderson, C. Bigam, M. Suto, 1998 .

2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)-carboxamide: a potent inhibitor of NF-kappa B- and AP-1-mediated gene expression identified using solution-phase combinatorial chemistry.

D. W. Anderson, C. Bigam, M. Suto, 1998, Journal of medicinal chemistry.

Interleukin-2 inhibitors in autoimmune disease

A. Manning, M. Palanki, 1999 .

Development of novel linkers to conjugate pharmacophores to a carrier antibody.

B. Liu, A. Bhat, R. Lappe, 2012, Bioorganic & medicinal chemistry letters.

Use of transferred nuclear overhauser effects to determine the conformation of 1-(3,4-dichlorophenyl)-2-aminopropane when bound to the active site of phenylethanolamine N-methyltransferace (PNMT)

M. Palanki, D. Velde, G. L. Grunewald, 1992 .

The Effect of a T Cell-Specific NF-κB Inhibitor on In Vitro Cytokine Production and Collagen-Induced Arthritis1

P. Tak, A. Manning, G. Firestein, 2000, The Journal of Immunology.

Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma.

F. López‐Soriano, S. Busquets, Maite Figueras, 2009, Anticancer research.